Percutaneous computed tomography-guided cryoablation for renal tumor: Experience in 30 cases

Lai, Wei-Jen; Chung, Hsiao-Jen; Chen, Chun-Ku; Shen, Shu-Huei; Chou, Hsiao-Ping; Chiou, Yi–You; Wang, Jia-Hwia; Chang, Cheng-Yen

doi:10.1016/j.jcma.2014.12.006

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a significant difference in the tumor size between the two groups in this study (P < 0.05, Mann-Whitney U test). Minimally invasive treatment, such as RFA and cryoablation, are established modalities for the treatment of small RCC without distant metastasis (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). The absence of distant metastasis should be confirmed before minimally invasive treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the use of minimally invasive treatments such as radiofrequency ablation (RFA) and cryoablation for T1a (tumor size 4 cm) renal cell carcinoma (RCC) without distant metastasis has been gradually increasing (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). The potential advantages of these procedures are good local control and a minimally invasive approach.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The additional utility of apparent diffusion coefficient values of clear-cell renal cell carcinoma for predicting metastasis during clinical staging

Yoshida

Yoshizako

Araki³

et al. 2017

Acta Radiologica Open

View full text Add to dashboard Cite

BackgroundThe apparent diffusion coefficient (ADC) value is known to be an indicator of tumor activity. The ADC value of high-grade clear-cell renal cell carcinoma (RCC) is significantly lower than that of low-grade clear-cell RCC.PurposeTo investigate the utility of ADC values of clear-cell RCC by comparing ADC values between groups with T1a RCC (tumor size ≤ 4 cm) without metastasis and the group with metastasis.Material and MethodsA retrospective review was performed on 51 patients with 51 RCCs who underwent 1.5 T magnetic resonance imaging (MRI) for evaluating a renal mass confirmed pathologically to be clear-cell RCC between January 2010 and August 2014. We compared ADC values between group A (T1a RCC without metastasis, T1aN0M0) and group B (RCC with metastasis) using the Mann–Whitney U test.ResultsThe patients were divided into group A (n = 30; tumor size: median, 24.5 mm; range, 8–40 mm; ADC value [×10−3 mm2/s]: median, 1.71; range, 1.23–2.24) and group B (n = 21; tumor size: median, 87.5 mm; range, 18–150 mm; ADC value [×10−3 mm2/s]: median, 1.35; range, 0.91–1.94). The ADC value differed significantly between the two groups. The area under the receiver operating characteristic curve was 0.869. Using the optimum cutoff value (1.552 × 10−3 mm2/s), ADC had a sensitivity of 80.0% and specificity of 81.0%.ConclusionThere was a statistically significant difference in the ADC between group A (T1a clear-cell RCC without distant metastasis) and group B (advanced clear-cell RCC with lymph node metastasis or distant metastasis).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The additional utility of apparent diffusion coefficient values of clear-cell renal cell carcinoma for predicting metastasis during clinical staging

Yoshida

Yoshizako

Araki³

et al. 2017

Acta Radiologica Open

View full text Add to dashboard Cite

show abstract

“…MIP is also a popular affinity ligand for electrochemical dopamine sensing, especially when combined with nanomaterials such as graphene, 131 CNTs, 132 QDs, 77 and NPG 133 . An electrochemical sensor displaying improved selectivity and sensitivity by Yang and co‐workers is shown in Figure 7B.…”

Section: Electochemical Biosensors Based On Oxidation Of Dopaminementioning

confidence: 99%

Biosensors and sensors for dopamine detection

Liu

2020

VIEW

196

122

View full text Add to dashboard Cite

Dopamine is a key catecholamine neurotransmitter and it has critical roles in the function of the human central nervous system. Abnormal release of dopamine is related to neurological diseases and depression. Therefore, it is necessary to monitor dopamine levels in vivo and in real time to understand its physiological roles. In this review, we discuss dopamine detection focusing on the molecular recognition methods including enzymes, antibodies, and aptamers, as well as new advances based on nanomaterials and molecularly imprinted polymers (MIPs). A large fraction of these sensors rely on electrochemical detection to fulfill the requirement of fast, in situ, and in vivo detection with a high spatial and temporal resolution. These methods need to overcome interferences from molecules with a similar redox potential. In addition, fluorescent and colorimetric sensors based on aptamers are also quite popular, and care needs to be taken to validate specific dopamine binding. Combining aptamers or MIPs with electrochemistry promises to achieve rapid detection and increased selectivity. In this article, we pay more attention to the molecular recognition mechanism and critically review the sensor designs. In the end, some future directions are discussed.

show abstract

“…Our study showed that PAS after renal cryoablation was generally early-onset and self-limiting with minimal effects on lifestyle and had mostly resolved by day 8. Recognition of the onset, severity, and duration of PAS may be helpful in distinguishing PAS from complications that show similar symptoms, such as urinary tract infection [14,15] and perirenal abscess [16,17], thereby facilitating prompt treatment of such complications.…”

Section: Discussionmentioning

confidence: 99%

Post-ablation syndrome after percutaneous cryoablation of small renal tumors: A prospective study of incidence, severity, duration, and effect on lifestyle

Kawabata

Hiraki

Iguchi

et al. 2020

European Journal of Radiology

View full text Add to dashboard Cite

To prospectively investigate the incidence, severity, duration, and effect on lifestyle of post-ablation syndrome (PAS) after percutaneous renal cryoablation. Materials and Methods: We enrolled 39 patients (27 male and 12 female; mean age, 62 years) who underwent 40 CT-guided cryoablation sessions for pathologically proven renal cancer (mean size, 20 mm) between December 2015 and December 2017. Four symptoms attributable to PAS, i.e., fever, nausea, vomiting, malaise, and the synergistic effect of these symptoms on lifestyle by 21 days after ablation were evaluated using a questionnaire. Symptoms were graded according to the common toxicity criteria of adverse events. Results: The incidences of fever, nausea, vomiting, and malaise were 100% (40/40), 20% (8/40), 20% (8/40), and 63% (25/40), respectively. Most (78/81, 96%) symptoms had begun by day 2. The highest grade of fever per session was 0 (defined as ≥37.0°C and < 38.0°C) (n = 24), 1 (n = 15), or 2 (n = 1); that of nausea was 2 (n = 8); that of vomiting was 1 (n = 7) or 3 (n = 1); and that of malaise was 1 (n = 14) or 2 (n = 11). Most (76/ 81, 94%) symptoms had resolved by day 8. The average values for the maximum scores of interference with general activity and work were 3.6 and 1.1, respectively. Conclusion: All symptoms were generally early-onset and self-limiting, with minimal impact on lifestyle and resolution by day 8. The clinical course and impact of PAS should be acknowledged by practitioners who manage patients undergoing renal cryoablation. [3]. Other studies showed that the incidences of PAS after hepatic and renal RF ablation were 89% (32/36) [4] and 32% (17/53) [5]. Wah et al. [4] demonstrated that PAS resolved more quickly after renal RF ablation than after hepatic RF ablation. To our knowledge, only one study focused on PAS after renal cryoablation, revealing an incidence of 63% (40/64) [6]. Deeper understanding of the clinical course and impact of PAS is still required for the management of patients undergoing renal cryoablation. We therefore aimed to evaluate the incidence, severity, duration, and lifestyle effect of PAS after percutaneous renal cryoablation.

show abstract

Percutaneous computed tomography-guided cryoablation for renal tumor: Experience in 30 cases

Abstract: Computed tomography-guided percutaneous cryoablation is a safe and effective technique for treating renal tumors with excellent renal function preservation.

Cited by 8 publications

References 26 publications

The additional utility of apparent diffusion coefficient values of clear-cell renal cell carcinoma for predicting metastasis during clinical staging

The additional utility of apparent diffusion coefficient values of clear-cell renal cell carcinoma for predicting metastasis during clinical staging

Biosensors and sensors for dopamine detection

Post-ablation syndrome after percutaneous cryoablation of small renal tumors: A prospective study of incidence, severity, duration, and effect on lifestyle

Contact Info

Product

Resources

About